These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 32706644)

  • 1. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
    Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
    [No Abstract]   [Full Text] [Related]  

  • 2. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.
    Koirala S; Borisov S; Danila E; Mariandyshev A; Shrestha B; Lukhele N; Dalcolmo M; Shakya SR; Miliauskas S; Kuksa L; Manga S; Aleksa A; Denholm JT; Khadka HB; Skrahina A; Diktanas S; Ferrarese M; Bruchfeld J; Koleva A; Piubello A; Koirala GS; Udwadia ZF; Palmero DJ; Munoz-Torrico M; Gc R; Gualano G; Grecu VI; Motta I; Papavasileiou A; Li Y; Hoefsloot W; Kunst H; Mazza-Stalder J; Payen MC; Akkerman OW; Bernal E; Manfrin V; Matteelli A; Mustafa Hamdan H; Nieto Marcos M; Cadiñanos Loidi J; Cebrian Gallardo JJ; Duarte R; Escobar Salinas N; Gomez Rosso R; Laniado-Laborín R; Martínez Robles E; Quirós Fernandez S; Rendon A; Solovic I; Tadolini M; Viggiani P; Belilovski E; Boeree MJ; Cai Q; Davidavičienė E; Forsman LD; De Los Rios J; Drakšienė J; Duga A; Elamin SE; Filippov A; Garcia A; Gaudiesiute I; Gavazova B; Gayoso R; Gruslys V; Jonsson J; Khimova E; Madonsela G; Magis-Escurra C; Marchese V; Matei M; Moschos C; Nakčerienė B; Nicod L; Palmieri F; Pontarelli A; Šmite A; Souleymane MB; Vescovo M; Zablockis R; Zhurkin D; Alffenaar JW; Caminero JA; Codecasa LR; García-García JM; Esposito S; Saderi L; Spanevello A; Visca D; Tiberi S; Pontali E; Centis R; D'Ambrosio L; van den Boom M; Sotgiu G; Migliori GB
    Pulmonology; 2021; 27(5):403-412. PubMed ID: 33753021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.
    Maretbayeva SM; Rakisheva AS; Adenov MM; Yeraliyeva LT; Algozhin YZ; Stambekova AT; Berikova EA; Yedilbayev A; Rich ML; Seung KJ; Issayeva AM
    Int J Infect Dis; 2021 Dec; 113 Suppl 1():S91-S95. PubMed ID: 33823277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
    Kempker RR; Mikiashvili L; Zhao Y; Benkeser D; Barbakadze K; Bablishvili N; Avaliani Z; Peloquin CA; Blumberg HM; Kipiani M
    Clin Infect Dis; 2020 Dec; 71(9):2336-2344. PubMed ID: 31712809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.
    Kho S; Seung KJ; Huerga H; Bastard M; Khan PY; Mitnick CD; Rich ML; Islam S; Zhizhilashvili D; Yeghiazaryan L; Nikolenko EN; Zarli K; Adnan S; Salahuddin N; Ahmed S; Vargas ZHR; Bekele A; Shaimerdenova A; Tamirat M; Gelin A; Vilbrun SC; Hewison C; Khan U; Franke M
    Nat Commun; 2024 May; 15(1):3927. PubMed ID: 38724531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
    Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Subay S; Adiono SH
    Int J Mycobacteriol; 2024 Apr; 13(2):140-146. PubMed ID: 38916383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis.
    Bhatnagar AK; Hemanthkumar AK; Muthu Vijayalakshmi M; Vohra V; Padmapriyadarsini C; Ramesh PM; Taneja G; Chavan VN; Jeyadeepa B; Bhui NK; Solanki R
    Ther Drug Monit; 2024 Jun; 46(3):363-369. PubMed ID: 38161267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
    Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M
    Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid.
    Chen Q; Huang T; Zou L; Tang X; Shi Z; Wang X; Wu H; Sun J; Lu X; Liang L; Jiang L; Liu D; Tang S; Wu G; He W
    Sci Rep; 2024 Jul; 14(1):17347. PubMed ID: 39069547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review.
    Putra ON; Yulistiani Y; Soedarsono S; Subay S
    Int J Mycobacteriol; 2023; 12(1):1-9. PubMed ID: 36926755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

  • 18. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
    N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.